CClinicalTrials.gg
CompletedNCT00267293Updated May 9, 2012Results posted

Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever

A Phase 4 interventional study of Acetaminophen and Ibuprofen in Fever, sponsored by Penn State University. Completed at 1 site in United States. Open to participants aged 6 Months to 7 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-05-09.

Sponsored by Penn State University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Months to 7 Years
Sex
All
01

Study summary

Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given. Both Ibuprofen and Acetaminophen are approved for over the counter use for treatment of fever by the Food and Drug Administration (FDA). This study hopes to determine whether giving both medications together is better than giving one medication alone for the treatment of fever.

Read the detailed description

Despite a lack of evidence to support their fears, a majority of parents, pediatricians, and pediatric nurses believe that fever can be dangerous to a child. This "fever phobia" has caused a majority of caregivers to aggressively treat fever with antipyretics such as ibuprofen and acetaminophen, often in combination. Although there is scant data to support the use of these medications together for fever control and none using alternating regimens, it was recently reported that 50% of pediatricians and 70% of pediatricians with less than 5 years of experience advise parents to alternate acetaminophen and ibuprofen as an attempt to achieve maximal antipyresis. While a combination of aspirin (no longer used for antipyresis in children) and acetaminophen has been shown to be superior to either agent alone for fever reduction, these data cannot be extrapolated to the pairing of ibuprofen and acetaminophen.

There is evidence that combinations of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are more effective for the treatment of pain and can reduce opioid use when compared with a single agent. Improved activity and alertness in children have been reported after antipyretic administration.

It is believed that acetaminophen and ibuprofen may be safely used together because the two medications have significantly different pathways of metabolism that are not affected by each other, and have been used abroad in combination form for over a decade. Both acetaminophen and ibuprofen have been shown to be safe when given individually or together in recommended doses for short term use. There are no reports of adverse effects from combination therapy with standard doses.

In addition, while it now appears that fever itself is probably a protective physiologic response, under different circumstances it has the potential to be harmful. Fever increases the metabolic rate approximately 10% for every 1 degree C rise in body temperature. The myocardial depression,orthostatic dysfunction, and increases in oxygen consumption, respiratory minute volume, and respiratory quotient that occur may not be tolerated by all patients including some children.

Because of the ubiquitous nature of the problem, childhood fever, this study has the potential to immediately impact the way clinicians and parents treat children with fever. If the combination regimens are not shown to be superior, it could limit improper medication administration and overdose. If it is superior, the combination of medications may improve other symptoms associated with fever such as discomfort. Either way, it will fill the gap that exists in the evidence-based approach to the management of childhood fever and immediately impact current practice.

02

Conditions studied

  • Fever

Browse trials for

Keywords

  • fever treatment
  • children
03

In context

Fever

601 studies on the registry are indexed under Fever; 102 are open to participants now.

This study's enrollment of 60 is below the median of 100 across 382 interventional studies indexed under Fever.

Browse Fever studies →

Lead sponsor

Penn State University is the lead sponsor of 263 studies on the registry; 51 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 10 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 7 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Age 6 months - 7 years of age at time of the fever.
  • Initial temperature of 38.0C (100.4F) or more.
  • Ability to cooperate with serial temporal artery temperature measurements.
  • Ability to take medications by mouth.
  • Willingness of the child's guardian/sponsor to give informed consent

Exclusion Criteria:

  • Patients who have received acetaminophen within 6 hours of presentation, or ibuprofen, aspirin, or other non-steroidal anti-inflammatory medications within 8 hours of presentation.
  • Patients >=3 years of age that have received narcotics in the previous 24 hours.
  • Children with weight >60 kg. Treatment of children with weights >60 kg will result in greater than recommended adult doses of the medications.
  • History of adverse reaction to any study medication ingredient.
  • History of diabetes mellitis, renal dysfunction, hepatic dysfunction, or thrombocytopenia.
  • Presence of moderate or severe dehydration.
  • Inclusion in the trial on 3 previous occasions
  • Medical judgment that the severity of the underlying illness prohibits inclusion.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    A

    At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg)

    Drug: Ibuprofen

  • Experimental
    B

    At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg)

    Drug: Acetaminophen · Drug: Ibuprofen

  • Experimental
    C

    At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate dose of Acetaminophen (15 mg/kg)

    Drug: Acetaminophen · Drug: Ibuprofen

Interventions

  • DrugAcetaminophen

    Given for fever control 15mg/kg

  • DrugIbuprofen

    Given for fever control 10 mg/kg

06

What researchers measure

Primary outcomes

  1. Child Temperature (Degrees C)Over 6 Hours

    Temperature was measured hourly using a temporal thermometer to monitor the child's temperature in degrees C. Temperature of 38 degrees C or higher was considered febrile.

    Time frame: 6 hours

07

Results

Posted May 9, 2012
Limitations and caveats
Relatively small sample size. Underpowered to evaluate effect oon discomfort and pain. The 6 hour observation allowed for evaluation of single cycle of drug. Did not evaluate the effect of multiple doses over a longer observation period.

Participant flow

Participant flow — Overall Study
MilestoneGroup A: Ibuprofen AloneGroup B: Ibuprofen and AcetaminophenGroup C: Ibuprofen Then Acetaminophen
Started202020
Completed202020
Not completed000

Outcome measures

PrimaryChild Temperature (Degrees C)Over 6 Hours

Temperature was measured hourly using a temporal thermometer to monitor the child's temperature in degrees C. Temperature of 38 degrees C or higher was considered febrile.

Time frame:
6 hours
Reported as:
Mean · degrees Celcius
Child Temperature (Degrees C)Over 6 Hours
degrees CelciusGroup A: Ibuprofen AloneGroup B: Ibuprofen and AcetaminophenGroup C: Ibuprofen Then Acetaminophen
Child Temperature (Degrees C)Over 6 Hours38.5 ± 1.537.2 ± 0.636.9 ± 0.3
Statistical analysis
  • Group A: Ibuprofen Alone vs Group B: Ibuprofen and Acetaminophen vs Group C: Ibuprofen Then Acetaminophen · Mixed Models Analysis · p = <0.001 (comparision of mean temperatures from repeated exposure. At hour 6 temperature)
  • Group A: Ibuprofen Alone vs Group B: Ibuprofen and Acetaminophen vs Group C: Ibuprofen Then Acetaminophen · Chi-squared · p = <.0001 (Binary outcome \<38C and \>=38C)

Adverse events

Collected over 6 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Ibuprofen Alone—0/20 (0%)0/20 (0%)
Group B: Ibuprofen and Acetaminophen—0/20 (0%)0/20 (0%)
Group C: Ibuprofen Then Acetaminophen—0/20 (0%)0/20 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group A: Ibuprofen AloneGroup B: Ibuprofen and AcetaminophenGroup C: Ibuprofen Then AcetaminophenTotal
<=18 years20202060
Between 18 and 65 years0000
>=65 years0000
Age Continuous
Age Continuous(years)Group A: Ibuprofen AloneGroup B: Ibuprofen and AcetaminophenGroup C: Ibuprofen Then AcetaminophenTotal
Mean3.2 ± 1.93.0 ± 1.94.0 ± 2.83.4 ± 2.2
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Ibuprofen AloneGroup B: Ibuprofen and AcetaminophenGroup C: Ibuprofen Then AcetaminophenTotal
Female8101331
Male1210729
Region of Enrollment
Region of Enrollment(participants)Group A: Ibuprofen AloneGroup B: Ibuprofen and AcetaminophenGroup C: Ibuprofen Then AcetaminophenTotal
United States20202060
08

Study locations

1 site
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033-0850, United States
09

References and documents

Publications

  • Paul IM, Sturgis SA, Yang C, Engle L, Watts H, Berlin CM Jr. Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children. Clin Ther. 2010 Dec;32(14):2433-40. doi: 10.1016/j.clinthera.2011.01.006. PubMed 21353111 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00267293
Lead sponsor
Penn State University
Collaborators
Children Youth and Family Consortium
Responsible party
Ian M. Paul, M.D., M.Sc. (Professor of Pediatrics and Public Health Sciences, Penn State University) — Principal investigator
First posted
Dec 20, 2005
Start date
Jan 2006
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
May 9, 2012
Last update
May 9, 2012

Study contacts

Ian M Paul, MD
principal investigator · Penn State Milton S. Hershey Children's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion